Midwest Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Midwest Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$50.2K	Hold	101	–	–	0.02%	95
2026 Q1	$45.1K	Hold	101	–	–	0.02%	99
2025 Q4	$45.8K	Hold	101	–	–	0.02%	91
2025 Q3	$39.6K	Hold	101	–	–	0.02%	95
2025 Q2	$45K	Hold	101	–	–	0.02%	90
2025 Q1	$49K	Hold	101	–	–	0.03%	86
2024 Q4	$40.7K	Buy	+101	New	+$46.8K	0.03%	97

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Midwest Capital Advisors's VRTX Position: Q2 2026 in Review

Midwest Capital Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 101 shares worth $50.2K. The position accounts for 0.02% of the portfolio, ranked #95.

Midwest Capital Advisors first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Midwest Capital Advisors held 101 shares of Vertex Pharmaceuticals worth $50.2K as of Q2 2026.
Midwest Capital Advisors left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.02% of Midwest Capital Advisors's portfolio in Q2 2026, its #95 holding.
Midwest Capital Advisors first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Midwest Capital Advisors's 13F filing for Q2 2026, filed 28 Jul 2026.